La vendita allo scoperto per Clearwater Analytics Hldg dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Clearwater Analytics Hldg. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Clearwater Analytics Hldg (NYSE:CWAN) Azioni, Report sulle vendite allo scoperto

Clearwater Analytics Hldg

Clearwater Analytics Holdings Inc provides a SaaS solution for automated investment data aggregation, reconciliation, accounting and reporting services to insurers, investment managers, corporations, institutional investors and government entities. It earns revenue from providing access to its SaaS platform to customers, services that support the implementation on the SaaS platform, selling perpetual and term-based software licenses and providing maintenance and support and professional services under contracts with customers. The majority of the revenue is earned in the United States.

Clearwater Analytics Holdings, Inc. Class A Common Stock

Clearwater Analytics Holdings Inc

News

Health Care

General

XELA

On November 6, 2024, The Nasdaq Stock Market Notified Exela Technologies That The Nasdaq Hearings Panel Has Determined To Delist The Company's Common Stock And That Trading Of The Company's Securities Will Be Suspended At The Open Of Trading On November 8-Filing

OTR Global downgrades Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from Mixed to Negative.

Downgrades

Analyst Ratings

PANW

OTR Global Downgrades Palo Alto Networks to Negative

Schwab Asset Management&#xAE;, the asset management arm of The Charles Schwab Corporation, today announced the launch of the Schwab Mortgage-Backed Securities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBS#NYSE">SMBS</a>). The first day of trading is expected to be on or about November 19.
With an expense ratio of 0.03%, the Schwab Mortgage-Backed Securities ETF is priced in line with the lowest-priced peer ETFs based on the U.S. Mortgage Lipper category1. The ETF will provide simple access to investment-grade mortgage-backed securities issued and/or guaranteed by U.S. government agencies. It is designed to serve as part of a diversified portfolio.

ETFs

SCHW

SMBS

Schwab Asset Management To Launch The Schwab Mortgage-Backed Securities ETF "SMBS" On Or About November 19

Buybacks

STGW

Stagwell Reveals $125M Increase In Stock Repurchase Program

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Hold.

Reiteration

GILD

Needham Reiterates Hold on Gilead Sciences

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587386a45064ed0001b4b61b/lauren-lieberman">Barclays analyst Lauren Lieberman</a> downgraded the rating for Coty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) from Equal-Weight to Underweight and lowered the price target from $8 to $7. Coty shares closed at $7.43 on Wednesday. <a href="https://www.benzinga.com/quote/COTY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Sean Milligan downgraded Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) from Hold to Underperform and cut the price target from $93 to $61. Enphase Energy shares closed at $74.81 on Wednesday. <a href="https://www.benzinga.com/quote/ENPH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Laura Champine downgraded the rating for Crocs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) from Buy to Hold and lowered the price target from $150 to $110. Crocs shares closed at $102.74 on Wednesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Toni Sacconaghi downgraded Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) from Outperform to Market Perform and announced a price target of $11. Ford shares closed at $11.19 on Wednesday. <a href="https://www.benzinga.com/quote/F/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59009b5a0bd9910001e5f2aa/bradley-thomas">Keybanc analyst Bradley Thomas </a>downgraded the rating for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from Overweight to Sector Weight. Dollar Tree shares closed at $62.41 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Ford stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-1024x586.png" alt="" class="wp-image-635158" style="width:545px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

COTY

CROX

DLTR

ENPH

This Ford Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

NKT Photonics to deliver three innovative prototype optical subsystems to IonQ in 2025
NKT Photonics' advanced laser systems will be integrated into IonQ's upcoming data center-ready quantum systems
IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leader in the quantum computing industry, announced today a partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nktphotonics.com%2F&amp;esheet=54148577&amp;newsitemid=20241107761716&amp;lan=en-US&amp;anchor=NKT+Photonics&amp;index=1&amp;md5=e2aeed3e06c83873b1e9149d1f342cf4">NKT Photonics</a>, a subsidiary of Hamamatsu Photonics, to procure next-generation laser systems for IonQ's trapped-ion quantum computers and networking equipment. The partnership involves NKT Photonics developing and delivering three prototype optical subsystems to IonQ in 2025, designed to support the commercialization of IonQ's data center-ready quantum computers – such as IonQ Tempo and future barium-based systems.

IONQ

IonQ Announces Partnership With NKT Photonics For Next-Generation Laser Systems To Power Future Quantum Computers

Guidance

Stagwell Reaffirms FY24 Guidance For Organic Net Revenue Growth Of 5% To 7%; Adjusted EBITDA Of $400M - $450M; Free Cash Flow Conversion Of ~50%

Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 65.35 percent increase over losses of $(1.27) per share from the same period last year.

Earnings

Earnings Beats

LPCN

Lipocine Q3 EPS $(0.44) Beats $(0.48) Estimate

FSTR

L.B. Foster Sees FY 2024 Net Sales $530M-$540M Vs $540.92M Est.

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $207 price target.

Price Target

JAZZ

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target

COEP

Coeptis Therapeutics Announces Phase 1 Data On DVX201 For COVID-19 Treatment Has Been Accepted For Publication in 'Molecular Therapy Methods and Clinical Development'

WK Kellogg Raises FY24 Adj. EBITDA Guidance; Sees FY24 Adj. EBITDA Growth Of 5%-6%

Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.72) by 11.11 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $354.62 million which beat the analyst consensus estimate of $225.00 thousand by 157.51K percent. This is a 110.90K percent increase over sales of $319.47 thousand the same period last year.

APRE

Aprea Therapeutics Q3 EPS $(0.64) Beats $(0.72) Estimate, Sales $354.62M Beat $225.00K Estimate

Endeavor Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDR#NYSE">EDR</a>) reported quarterly sales of $2.03 billion which beat the analyst consensus estimate of $1.56 billion by 30.29 percent. This is a 51.12 percent increase over sales of $1.34 billion the same period last year.

Endeavor Q3 EPS From Cont. Ops $(0.44), Down From $(0.24) Last Year, Sales $2.03B, Up From $1.22B Prior Year

L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) reported quarterly earnings of $3.27. The company reported quarterly sales of $137.50 million which missed the analyst consensus estimate of $141.78 million by 3.02 percent. This is a 5.40 percent decrease over sales of $145.34 million the same period last year.

Earnings Misses

L.B. Foster Q3 2024 GAAP EPS $3.27, Sales $137.50M Miss $141.78M Estimate

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.26 by 19.23 percent. The company reported quarterly sales of $689.000 million which beat the analyst consensus estimate of $674.044 million by 2.22 percent. This is a 0.43 percent decrease over sales of $692.000 million the same period last year.

WK Kellogg Q3 2024 Adj. EPS $0.31 Beats $0.26 Estimate, Sales $689.000M Beat $674.044M Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy and maintains $100 price target.

KROS

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target

HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.42) by 23.81 percent. This is a 35.8 percent increase over losses of $(0.81) per share from the same period last year.

HLVX

HilleVax Q3 EPS $(0.52) Misses $(0.42) Estimate

Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.40) by 15 percent. This is a 8.11 percent increase over losses of $(0.37) per share from the same period last year.

IMNN

Imunon Q3 2024 GAAP EPS $(0.34) Beats $(0.40) Estimate. Cash and Equivalents of $10.3M

Reports Q3 revenue $115.8M, consensus $113.43M. "It's very gratifying to see continued excellence in execution. Our results are truly outstanding –...

Clearwater Analytics reports Q3 EPS 12c, consensus 11c

The latest update is out from Clearwater Analytics Holdings ( ($CWAN) ). Clearwater Analytics has amended its Tax Receivable Agreement, agreeing to...

Clearwater Analytics Settles Agreement and Reports Strong Q3

Clearwater Analytics Non-GAAP EPS of $0.12 beats by $0.01, revenue of $115.8M beats by $2.37M

Clearwater Analytics Holdings, Inc. Class A ( ($CWAN) ) has released its Q3 earnings. Here is a breakdown of the information Clearwater Analytics H...

Clearwater Analytics Reports Strong Q3 2024 Financial Results

Clearwater Analytics Holdings, Inc. (CWAN) Q3 2024 Earnings Conference Call Transcript

In a report released today, Dylan Becker from William Blair maintained a Buy rating on Clearwater Analytics Holdings (CWAN – Research Report). The ...

William Blair Sticks to Its Buy Rating for Clearwater Analytics Holdings (CWAN)

JPMorgan upgraded Clearwater Analytics (CWAN) to Overweight from Neutral with a price target of $33, up from $23, following the "strong" Q3 report....

Clearwater Analytics upgraded to Overweight from Neutral at JPMorgan

Clearwater Analytics Holdings (CWAN – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Alexei...

Clearwater Analytics Holdings: Accelerated Growth, Strategic Partnerships, and Upgraded Buy Rating

Oppenheimer analyst Brian Schwartz raised the firm's price target on Clearwater Analytics (CWAN) to $35 from $31 and keeps an Outperform rating on ...

Clearwater Analytics price target raised to $35 from $31 at Oppenheimer

Piper Sandler raised the firm's price target on Clearwater Analytics (CWAN) to $28 from $23 and keeps a Neutral rating on the shares. The firm note...

Comments

Clearwater Analytics Hldg

Vendite allo scoperto

Clearwater Analytics Hldg (NYSE:CWAN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO